Institute for Breathing and Sleep, Austin Health, Heidelberg, Australia.
Sleep. 2012 Jan 1;35(1):41-8. doi: 10.5665/sleep.1582.
To determine whether cerebral metabolite changes may underlie abnormalities of neurocognitive function and respiratory control in OSA.
Observational, before and after CPAP treatment.
Two tertiary hospital research institutes.
30 untreated severe OSA patients, and 25 age-matched healthy controls, all males free of comorbidities, and all having had detailed structural brain analysis using voxel-based morphometry (VBM).
Single voxel bilateral hippocampal and brainstem, and multivoxel frontal metabolite concentrations were measured using magnetic resonance spectroscopy (MRS) in a high resolution (3T) scanner. Subjects also completed a battery of neurocognitive tests. Patients had repeat testing after 6 months of CPAP. There were significant differences at baseline in frontal N-acetylaspartate/choline (NAA/Cho) ratios (patients [mean (SD)] 4.56 [0.41], controls 4.92 [0.44], P = 0.001), and in hippocampal choline/creatine (Cho/Cr) ratios (0.38 [0.04] vs 0.41 [0.04], P = 0.006), (both ANCOVA, with age and premorbid IQ as covariates). No longitudinal changes were seen with treatment (n = 27, paired t tests), however the hippocampal differences were no longer significant at 6 months, and frontal NAA/Cr ratios were now also significantly different (patients 1.55 [0.13] vs control 1.65 [0.18] P = 0.01). No significant correlations were found between spectroscopy results and neurocognitive test results, but significant negative correlations were seen between arousal index and frontal NAA/Cho (r = -0.39, corrected P = 0.033) and between % total sleep time at SpO(2) < 90% and hippocampal Cho/Cr (r = -0.40, corrected P = 0.01).
OSA patients have brain metabolite changes detected by MRS, suggestive of decreased frontal lobe neuronal viability and integrity, and decreased hippocampal membrane turnover. These regions have previously been shown to have no gross structural lesions using VBM. Little change was seen with treatment with CPAP for 6 months. No correlation of metabolite concentrations was seen with results on neurocognitive tests, but there were significant negative correlations with OSA severity as measured by severity of nocturnal hypoxemia.
确定脑代谢物的变化是否是 OSA 患者神经认知功能和呼吸控制异常的基础。
观察性,CPAP 治疗前后。
两个三级医院研究所。
30 名未经治疗的严重 OSA 患者和 25 名年龄匹配的健康对照者,均为无合并症的男性,均使用基于体素的形态计量学(VBM)进行了详细的结构脑分析。
使用磁共振波谱(MRS)在高分辨率(3T)扫描仪中测量了单个双侧海马体和脑桥的体素以及多体素额叶代谢物浓度。受试者还完成了一系列神经认知测试。患者在 CPAP 治疗 6 个月后进行了重复测试。在基线时,额叶 N-乙酰天冬氨酸/胆碱(NAA/Cho)比值(患者[平均值(SD)] 4.56 [0.41],对照组 4.92 [0.44],P = 0.001)和海马胆碱/肌酸(Cho/Cr)比值(0.38 [0.04]与 0.41 [0.04],P = 0.006)存在显著差异,(均为 ANCOVA,以年龄和预患病智商为协变量)。治疗后未见纵向变化(n = 27,配对 t 检验),但是 6 个月时海马体差异不再显著,并且额叶 NAA/Cr 比值现在也有显著差异(患者 1.55 [0.13] vs 对照组 1.65 [0.18],P = 0.01)。MRS 结果与神经认知测试结果之间未发现显著相关性,但在觉醒指数与额叶 NAA/Cho 之间(r = -0.39,校正 P = 0.033)和总睡眠时间百分比在 SpO(2)<90%与海马体 Cho/Cr 之间(r = -0.40,校正 P = 0.01)呈显著负相关。
OSA 患者通过 MRS 检测到脑代谢物变化,提示额叶神经元活力和完整性降低,海马体膜周转率降低。以前使用 VBM 已经显示这些区域没有明显的结构病变。CPAP 治疗 6 个月后变化不大。代谢物浓度与神经认知测试结果无相关性,但与夜间低氧血症严重程度(即 OSA 严重程度)呈显著负相关。